This effect appears to be primarily on tumors that express the estrogen receptor (ER) and/or progesterone receptor (PR); in contrast, risk for ER/PR negative and triple negative breast cancers is increased (80% increased risk per 5 kg per m2) [15]. Here, ESR1 is linked to triple-negative breast carcinoma.